This week, Neurology News Network covered Impel NeuroPharma’s nasal DHE agent, INP104, and the launch of its phase 3 STOP 301 trial; Wave Life Science’s investigational stereopure oligonucleotide suvodirsen receiving FDA fast track designation; and a new analysis of the EXPAND study population treated with siponimod.
Ещё видео!